Yellowstone Biosciences Ltd, an Oxford University, UK, spinout developing selective cancer therapeutics, has appointed James MacDonald as chief executive officer. Mr MacDonald’s more than 25 years of experience includes scaling high-growth biotech companies, advancing novel oncology platforms and strategic financing.
He was most recently venture partner at Altitude Life Science Ventures and previously, he was co-founder, executive vice president & general counsel at Sana Biotechnology, where he played a key role in building and scaling the business, undertaking its private financings as well as its Nasdaq IPO. Yellowstone is advancing soluble bispecific T-cell receptor (TCR)-based therapies targeting human leukocyte antigen (HLA) Class II antigens, initially focused on acute myeloid leukaemia and solid tumours.
Yellowstone Biosciences announced the appointment on 16 September 2025.
Copyright 2025 Evernow Publishing Ltd.